<< Muscle Flex CEO to promote Muscle Flex brands | Pioneering cardiologist and inventor in heart medicine passed away >>
Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Русский | Svenska | Polski

ORC Guideline's recent research on the impact of social media and pharmaceutical marketing

Published on November 12, 2009 at 4:52 AM · No Comments

Chief Research Officer Morris S. Whitcup, Ph.D., of ORC Guideline (an infoGROUP company) (NASDAQ: IUSA) will present findings of the company’s recent research on the impact of social media on fair balance and pharmaceutical marketing at a Food and Drug Administration (FDA) public hearing later this week. The hearing will address the issue of fulfilling requirements for fair balance and risk disclosure in internet and social media promotions. The ORC Guideline study examined consumer habits in researching information about pharmaceutical products online.

“These hearings are vitally important for the pharmaceutical industry, as one in five consumers indicated that they use social media to research prescription medication and obtain information about diseases,” said Dr. Whitcup. “The FDA has increasingly paid attention to promotion in social media to ensure that regulations relating to required disclosures and fair balance are met.”

Dr. Whitcup's presentation, which will include recommendations to the FDA on new approaches to communicating risk information, will be held on Friday, November 13th, at 1:20pm Eastern in Washington, DC. The FDA will also provide access to a free, live webcast of this public hearing. More information about the webcast can be found at http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm184250.htm.


Source: infoGROUP

Posted in: Pharmaceutical News

Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.



  Country flag

biuquote
  • Comment
  • Preview
Loading